A rumor making the rounds says a large activist may be getting involved with Intercept Pharma (NASDAQ:ICPT) to push for sale.
Intercept disappointed in late June when it received a CRL from the FDA for its application for the use of obeticholic acid (OCA) to treat liver fibrosis due to nonalcoholic steatohepatitis (NASH). Shares fell about 40% that day, and have slipped a bit further since.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.